Chen, Joyce
López-Moyado, Isaac F.
Seo, Hyungseok
Lio, Chan-Wang J.
Hempleman, Laura J.
Sekiya, Takashi
Yoshimura, Akihiko
Scott-Browne, James P.
Rao, Anjana
Article History
Received: 31 December 2017
Accepted: 29 January 2019
First Online: 27 February 2019
Competing interests
: The La Jolla Institute of Immunology has a pending patent, PCT/US2018/062354, covering the use and production of engineered immune cells to disrupt NFAT-AP1 pathway transcription factors, including the NR4A family members, with J.C., H.S., J.P.S-B. and A.R. listed as inventors. A.R. receives funding from Takeda for subsequent research related to this subject matter. None of the other authors has any competing interests.